F. Zsigmond

Perianal disease, small bowel disease, smoking, prior steroid or early azathioprine/biological therapy are predictors of disease behavior change in patients with Crohn's disease.

P. Lakatos, J. Papp, J. Banai, 2009, World journal of gastroenterology.

Efficacy and Safety of Adalimumab in Ulcerative Colitis Refractory to Conventional Therapy in Routine Clinical Practice.

K. Farkas, F. Nagy, T. Molnár, 2016, Journal of Crohn's & colitis.

Early azathioprine/biological therapy is associated with decreased risk for first surgery and delays time to surgery but not reoperation in both smokers and nonsmokers with Crohn's disease, while smoking decreases the risk of colectomy in ulcerative colitis

M. Papp, P. Lakatos, J. Papp, 2010, European journal of gastroenterology & hepatology.

Efficacy and Safety of Budesonide, vs Mesalazine or Placebo, as Induction Therapy for Lymphocytic Colitis.

P. Hellström, L. Kupčinskas, F. Nagy, 2018, Gastroenterology.

Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study

K. Farkas, F. Nagy, T. Molnár, 2019, Expert opinion on biological therapy.

Safety Precautions for Self-Performed Severe Acute Respiratory Syndrome Coronavirus 2 Tests: A Case of a Swallowed Swab

F. Zsigmond, Dávid Molnár, F. Helfferich, 2021, Cureus.

A 1-year trial of repeated high-dose intravenous iron isomaltoside 1000 to maintain stable hemoglobin levels in inflammatory bowel disease

W. Reinisch, G. Novacek, H. Vogelsang, 2015, Scandinavian journal of gastroenterology.